Denali Therapeutics Inc. (DNLI)
Nasdaq: DNLI · Biological Products, (No Diagnostic Substances) · South San Francisco, CA · filing with the SEC since 2017
Who owns Denali Therapeutics Inc.
As filed with the SECHolders of 5% or more
3
T. Rowe Price Investment Management, Inc. holds 10.2% of COMMON STOCK, as its SCHEDULE 13G/A filed Jul 8, 2026 says.
Directors and officers
17
report now, of 22 people on the record since 2017. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
T. Rowe Price Investment Management, Inc.
SCHEDULE 13G/A · filed Jul 8, 2026 · COMMON STOCK · 5.4% in May 15, 2026
Baillie Gifford & Co
SCHEDULE 13G/A · filed Aug 4, 2026 · Common Stock · 8.6% in Feb 12, 2025
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 17, 2025 · Common Stock
Fmr LLC
SCHEDULE 13G/A · filed May 6, 2026 · COMMON STOCK · reported falling below 5%, from 5.8% in Nov 5, 2025
Wellington Management Group LLP
SCHEDULE 13G/A · filed Aug 12, 2025 · Common Stock · reported falling below 5%
Capital Research Global Investors
SCHEDULE 13G/A · filed Feb 13, 2025 · Common Stock · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
What DNLI reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Sanofi
An entity · legal entity · owns, named in the 10-K filed Feb 26, 2026
2 subsidiaries in 2 countries, from the list filed with the 10-K filed Feb 26, 2026.
Insider tradesForm 4
7sales
0purchases
3sales on a scheduled plan
4people selling
$1.3Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 42 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Watts Ryan J. | President and CEO | 1 | $600,000 | 0 | 0 | $0 |
| Schuth Alexander O. | COFO and Secretary | 3 | $400,000 | 1 | 0 | $0 |
| Thornberry Nancy | director | 2 | $300,000 | 2 | 0 | $0 |
| Chin Peter Scott | Chief Medical Officer | 1 | $0 | 0 | 0 | $0 |